Skip to content

A prospective real-world cohort study on the effects of single-target and multi-target GLP-1 receptor agonists and bariatric surgery on food craving and mental health in obese patients

A prospective real-world cohort study on the effects of single-target and multi-target GLP-1 receptor agonists and bariatric surgery on food craving and mental health in obese patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124497
Enrollment
Unknown
Registered
2026-05-13
Start date
2026-05-15
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

Lifestyle Observation Group:None
Single-target drug observation group:None
Multi-target drug observation group:None
The observation group of sleeve gastrectomy:None

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18 - 65 years old, gender not restricted; 2. Meets the diagnostic criteria for obesity in China (BMI >= 28 kg/m^2, or BMI >= 24 kg/m^2 with metabolic comorbidities); 3. Voluntarily selects one of the four intervention methods and signs the informed consent form; 4. Has basic reading and writing skills and can cooperate to complete the psychological scale assessment.

Exclusion criteria

Exclusion criteria: 1. Baseline screening indicated a significant psychological risk (PHQ-9 suicide ideation item >= 1 point, or GAD-7 >= 15 points / PHQ-9 >= 20 points indicating the need for specialized intervention for severe anxiety/depression); 2. Previously diagnosed with severe mental disorders such as schizophrenia or bipolar disorder; 3. Have a history of substance abuse in the past 3 months; 4. Pregnant or lactating women; 5. Have severe and uncontrolled systemic diseases (such as malignant tumors, important organ failure); 6. Have participated in other drug clinical trials in the past 3 months.

Design outcomes

Primary

MeasureTime frame
Percentage of total body weight loss;Weight loss-related quality of life;

Secondary

MeasureTime frame
Food craving;Anxiety symptoms;Depressive symptoms;Behavior and addiction;

Countries

China

Contacts

Public ContactXiaohai Song

West China Hospital, Sichuan University

1282825332@qq.com+86 184 8462 2465

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026